Association Between Human Papillomavirus (HPV) Infection and Neisseria Gonorrhea Among Women Screened for HPV in A Rural Community, Southwest Nigeria: A Case-Control Study

Why It Matters

If HPV infection predisposes women to gonorrhea, integrated STI screening could improve cervical cancer prevention. Understanding co‑infection dynamics informs public‑health strategies in low‑resource settings.

Key Takeaways

• HPV‑positive women had higher gonorrhea prevalence (6.45% vs 1.1%).
• Odds ratio of co‑infection was 6.33, not statistically significant.
• All co‑infections occurred in women younger than 35.
• Sample size limited statistical power; larger studies recommended.
• Findings suggest potential link between HPV and gonorrhea.

Pulse Analysis

The interplay between human papillomavirus (HPV) and other sexually transmitted infections (STIs) has long intrigued epidemiologists, because co‑infection can modify viral persistence and disease progression. HPV is the primary etiologic agent of cervical cancer, yet its natural history is influenced by host immunity, sexual behavior, and the presence of bacterial pathogens such as Neisseria gonorrhoeae. Gonorrhea induces mucosal inflammation, potentially creating a microenvironment that facilitates HPV entry or hampers clearance. Understanding these biological synergies is especially critical in low‑resource regions where screening programs are nascent and STI burden remains high.

The recent case‑control investigation from a rural community in Southwest Nigeria adds a data point to this debate. Among 186 women with archived self‑collected vaginal samples, 6.45 % of HPV‑positive participants harbored gonorrhea, compared with only 1.1 % of HPV‑negative controls, translating to an odds ratio of 6.33. Although the association did not achieve statistical significance—likely due to the modest sample size—the concentration of co‑infections in women under 35 underscores a demographic at heightened risk. These results hint that HPV screening could serve as a trigger for broader STI testing.

For policymakers, the implication is clear: integrating HPV and gonorrhea diagnostics within a single outreach platform could improve case detection while optimizing limited laboratory capacity. Such bundled approaches have shown cost‑effectiveness in other sub‑Saharan settings, reducing missed opportunities for early intervention. Moreover, the study highlights the necessity of larger, longitudinal cohorts to disentangle causality from correlation and to assess whether treating gonorrhea influences HPV clearance rates. As global health agendas push toward cervical cancer elimination, acknowledging and addressing STI co‑factors will be essential for achieving sustainable impact.